Indolyl aryl sulphones as HIV-1 reverse transcriptase inhibitors: Docking and 3D QSAR studies

Expert Opinion on Drug Discovery

Volumn 2, Issue 1, 2007, Pages 87-114

  Ragno, Rino ^a   Coluccia, Antonio ^a   La Regina, Giuseppe ^a   Silvestri, Romano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

3D QSAR; Docking; HIV 1; Indolyl aryl sulphone; NNRTI; RT

Indexed keywords

(4 METHOXY 2 NITROPHENYL)PHENYLSULFONE; 1 ARYLSULFONYL 5 CHLOROINDOLE DERIVATIVE; 2 CHLORO 5H INDOLO[3,2 B][1,5]BENZOTHIAZEPI 6(7H) ONE; 3 [(2 AMINO 5 CHLOROPHENYL)SULFONYL] 5 CHLOROINDOLO 2 CARBOXAMIDE; 3 ARYLSULFONYL 5 CHLOROINDOLE DERIVATIVE; ANTIRETROVIRUS AGENT; BENZOTHIADIAZEPINE DERIVATIVE; EFAVIRENZ; INDOLYL ARYL SULFONE DERIVATIVE; L 737126; LIGAND; NEVIRAPINE; NITROPHENYL PHENYL SULFONE SERIVATIVE; PYRROL[3,2 B][1,2,5] BENZOTHIAZEPINE; PYRROLO[2,3 B][1,5] BENZOTHIAZEPINE; PYRROLO[2,3 B][1,5] BENZOTHIAZEPINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; BINDING AFFINITY; BINDING SITE; CONFORMATIONAL TRANSITION; CYTOTOXICITY; DRUG DESIGN; DRUG SCREENING; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; MUTANT; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; VIRUS STRAIN;

EID: 34447527787     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.1.87     Document Type: Review

References (66)

1. NO AUTHORS LISTED: UNAIDS forecasts future of global progression of HIV/ AIDS. AIDS Policy Law (2005) 20(8):1,4.
2. NO AUTHORS LISTED: Opportunistic infections and Kaposi's sarcoma among Haitians in the United States. MMWR Moth. Mortal. Wkly Rep. (1982) 31(26):353-354, 360-351.
3. GUYADER M, EMERMAN M, SONIGO P, CLAVEL F, MONTAGNIER L, ALIZON M: Genome organization and transactivation of the human immunodeficiency virus type 2. Nature (1987) 326(6114):662-669.
4. NEAMATI N, SUNDER S, POMMIER Y: Design and discovery of HIV-1 integrase inhibitors. Drug Discov. Today (1997) 2(11):487-498.
5. DE CLERCQ E: New perspectives for the treatment of HIV infections. Verh. K. Acad. Geneeskd Belg. (1998) 60(1):13-41; discussion 41-45.
6. DE CLERCQ E: Highlights in the development of new antiviral agents. Mini Rev. Med. Chem. (2002) 2(2):163-175.
7. DE CLERCQ E: Emerging anti-HIV drugs. Expert Opin. Emerg. Drugs (2005) 10(2):241-273.
8. REEVES JD, PIEFER AJ: Emerging drug targets for antiretroviral therapy. Drugs (2005) 65(13): 1747-1766.
9. TEMESGEN Z, WARNKE D, K ASTEN MJ: Current status of antiretroviral therapy. Expert Opin. Pharmacother. (2006) 7(12):1541-1554.
10. VIVET-BOUDOU V, DIDIERJEAN J, ISEL C, MARQUET R: Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell. Mol. Life Sci. (2006) 63(2):163-186.
11. GARCIA-GASCO P, BLANCO F, SORIANO V: Integrase inhibitors. J. HIV Ther. (2005) 10(4):75-78.
12. DAUER B: Protease inhibitors: the current status. J. HIV Ther. (2005) 10(4):72-74.
13. CHENG YC, DUTSCHMAN GE, BASTOW KF, SARNGADHARAN MG, TING RY: Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J. Biol. Chem. (1987) 262(5):2187-2189.
14. JACOBO-MOLINA A, CLARK AD Jr, WILLIAMS RL et al.: Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody lab fragment and double-stranded DNA diffract X-rays to 3.5-A resolution. Proc. Natl. Acad. Sci. USA (1991) 88(23):10895-10899.
15. JACOBO-MOLINA A, DING J, NANNI RG et al.: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. USA (1993) 90(13):6320-6324.
16. RODGERS DW, GAMBLIN SJ, HARRIS BA et al.: The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA (1995) 92(4):1222-1226.
17. COHEN J: Therapies. Raising the limits. Science (2002) 296(5577):2322.
18. COHEN KA, HOPKINS J, INGRAHAM RH et al.: Characterization of the binding site for nevirapine (BI-RG-587) a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J. Biol. Chem. (1991) 266(22): 14670-14674.
19. VANDAMME AM, VAN VAERENBERGH K, DE CLERCQ E: Anti-human immunodeficiency virus drug combination strategies. Antivir. Chem. Chemother. (1998) 9(3):187-203.
20. CARPENTER CC, COOPER DA, FISCHL MA et al.: Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 283(3):381-390.
21. COONEY EL: Clinical indicators of immune restoration following highly active antiretroviral therapy. Clin. Infect. Dis. (2002) 34(2):224-233.
22. DE CLERCQ E, BALZARINI J: Knocking out human immunodeficiency virus through non-nucleoside reverse transcriptase inhibitors used as single agents or in combinations: a paradigm for the cure of AIDS? Farmaco (1995) 50(11):735-747.
23. MERLUZZI VJ, HARGRAVE KD, LABADIA M et al.: Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science (1990) 250(4986):1411-1413.
24. ROMERO DL, MORGE RA, GENIN MJ et al.: Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido- 1H-indol-2-yl)- carbonyl]-4-[3-[(1- methylethyl)amino]- pyridinyl]piperazin e monomethanesulfonate (U-90152S) a second-generation clinical candidate. J. Med. Chem. (1993) 36(10):1505-1508.
25. YOUNG SD, BRITCHER SF, TRAN LO et al.: L-743, 726(DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. (1995) 39(12):2602-2605.
26. PETROPOULOS CJ, PARKIN NT, LIMOLI KL et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus Type 1. Antimicrob. Agents Chemother. (2000) 44(4):920-928.
27. BYRNES VW, EMINI EA, SCHLEIF WA et al.: Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrob. Agents Chemother. (1994) 38(6):1404-1407.
28. HUANG H, CHOPRA R, VERDINE GL, HARRISON SC: Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science (1998) 282(5394):1669-1675.
29. FUJIWARA T, SATO A, EL-FARRASH M et al.: S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (1998) 42(6):1340-1345.
30. MCMAHON JB, GULAKOWSKI RJ, WEISLOW OS et al.: Diarylsulfones, a new chemical class of nonnucleoside antiviral inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. (1993) 37(4):754-760.
31. ARTICO M, SILVESTRI R, STEFANCICH G et al.: Synthesis of pyrryl aryl sulfones targeted at the HIV-1 reverse transcriptase. Arch. Pharm. Weinheim (1995) 328(3):223-229.
32. WILLIAMS TM, CICCARONE TM, MACTOUGH SC et al.:5-chloro-3-(phenylsulfonyl)indole-2-c arboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. J. Med. Chem. (1993) 36(9):1291-1294.
33. ARTICO M, SILVESTRI R, MASSA S et al.: 2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus Type 1 activity of pyrrolyl aryl sulfones. J. Med. Chem. (1996) 39(2):522-530.
34. KUKLA MJ, BRESLIN HJ, DIAMOND CJ et al.: Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-j k][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2. J. Med. Chem. (1991) 34(11):3187-3197.
35. KUKLA MJ, BRESLIN HJ, PAUWELS R et al.: Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-j k][1,4]benzodiazepin-2(1H)-one(TIBO) derivatives. J. Med. Chem. (1991) 34(2):746-751.
36. ARTICO M, SILVESTRI R, PAGNOZZI E et al.: 5H-pyrrolo[1,2-b] [1,2,5]benzothiadiazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. (1996) 4(6):837-850.
37. ARTICO M, STEFANCICH G, SILVESTRI R et al.: Pyrrolobenzothiazepines: a new class of nonnucleoside HIV-1 reverse transcriptase inhibitors. Med. Chem. Res. (1994) 4(4):283-290.
38. SILVESTRI R, ARTICO M, DE MARTINO G et al.: Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitr oimidazoles targeted at the HIV-1 reverse transcriptase. J. Med. Chem. (2002) 45(8):1567-1576.
39. DING J, DAS K, MOEREELS H, KOYMANS L et al.: Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. (1995) 2(5):407-415.
40. ARTICO M, SILVESTRI R, PAGNOZZI E et al.: Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. J. Med. Chem. (2000) 43(9):1886-1891.
41. SILVESTRI R, ARTICO M, DE MARTINO G et al.: Computer-assisted design, synthesis and biological evaluation of novel pyrrolyl heteroaryl sulfones targeted at HIV-1 reverse transcriptase as non-nucleoside inhibitors. Bioorg. Med. Chem. (2000) 8(9):2305-2309.
42. SILVESTRI R, DE MARTINO G, LA REGINA G et al.: Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. J. Med. Chem. (2003) 46(12):2482-2493.
43. GOODSELL DS, MORRIS GM, OLSON AJ: Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. (1996) 9(1):1-5.
44. RAGNO R, MAI A, MASSA S, CERBARA I et al.: 3-(4-Aroyl-1-methyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides as a new class of synthetic histone deacetylase inhibitors. 3. Discovery of novel lead compounds through structure-based drug design and docking studies. J. Med. Chem. (2004) 47(6):1351-1359.
45. RAGNO R, MAI A, SBARDELLA G et al.: Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alky 1]-3,4-dihydro-5-alkylpyrimidin-4(3H)-one s as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J. Med. Chem. (2004) 47(4):928-934.
46. RAGNO R, FRASCA S, MANETTI F, BRIZZI A, MASSA S: HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies. J. Med. Chem. (2005) 48(1):200-212.
47. CRUCIANI G, WATSON KA: Comparative molecular field analysis using GRID force-field and GOLPE variable selection methods in a study of inhibitors of glycogen phosphorylase b. J. Med. Chem. (1994) 37(16):2589-2601.
48. ARTICO M, BOTTA M, CORELLI F, MAI A, MASSA S, RAGNO R: Investigation on QSAR and binding mode of a new class of human rhinovirus-14 inhibitors by CoMFA and docking experiments. Bioorg. Med. Chem. (1996) 4(10):1715-1724.
49. DI SANTO R, COSTI R, ARTICO M et al.: Design, synthesis and QSAR studies on N-aryl heteroarylisopropanolamines, a new class of non-peptidic HIV-1 prorease inhibitors. Bioorg. Med. Chem. (2002) 10(8):2511-2526.
50. RAGNO R, MARSHALL GR, DI SANTO R et al.: Antimycobacterial pyrroles: synthesis, anti-Mycobacterium tuberculosis activity and QSAR studies. Bioorg. Med. Chem. (2000) 8(6):1423-1432.
51. RAGNO R, ARTICO M, DE MARTINO G et al.: Docking and 3D QSAR studies on indolyl aryl sulfones. binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N- (2-hydroxyethyl)carbohydrazide derivatives. J. Med. Chem. (2005) 48(1):213-223.
52. CHAN JH, HONG JS, HUNTER RNR et al.: 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. J. Med. Chem. (2001) 44(12):1866-1882.
53. GOODFORD PJ: A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. (1985) 28(7):849-857.
54. BARONI M, COSTANTINO G, CRUCIANI G, RIGANELLI D, VALIGI R, CLEMENTI S: Generating optimal linear PLS estimations (GOLPE): An advanced chemometric tool for handling 3D-QSAR problems. Quant. Struct.-Act. Relat. (1993) 12:9-20.
55. PASTOR M, CRUCIANI G, CLEMENTI S: Smart region definition: a new way to improve the predictive ability and interpretability of three-dimensional quantitative structure-activity relationships. J. Med. Chem. (1997) 40(10):1455-1464.
56. WASLEY JWF: Molecular Interaction Fields. vol 49; G Cruciani (Ed) (2006).
57. YOUNG SD, AMBLARD MC, BRICHTER SF et al.: 2-Heterocyclic indole-3-sulfones as inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. (1995) 5:491-496.
58. SILVESTRI R, ARTICO M, DE MARTINO G et al.: Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. J. Med. Chem. (2004)47(15):3892-3896.
59. HOPKINS AL, REN J, MILTON J et al.: Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. J. Med. Chem. (2004) 47(24):5912-5922.
60. DE MARTINO G, LA REGINA G, RAGNO R et al.: Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide. Antivir. Chem. Chemother. (2006) 17(2):59-77.
61. KOHLSTAEDT LA, WANG J, FRIEDMAN JM, RICE PA, STEITZ TA: Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 256(5065):1783-1790.
62. REN J, ESNOUF R, GARMAN E, SOMERS D et al.: High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. (1995) 2(4):293-302.
63. REN J, NICHOLS C, BIRD L et al.: Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. MoL Biol. (2001) 312(4):795-805.
64. REN J, MILTON J, WEAVER KL, SHORT SA, STUART DI, STAMMERS DK: Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Struct. Fold Des. (2000) 8(10):1089-1094.
65. TETKO IV, TANCHUK VY, KASHEVA TN, VILLA AE: Estimation of aqueous solubility of chemical compounds using E-state indices. J. Chem. Inf. Comput. Sci. (2001) 41(6):1488-1493.
66. RAGNO R, COLUCCIA A, LA REGINA G et al.: Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide. J. Med. Chem. (2006) 49(11):3172-3184.